---
schema_version: "secwatch.filing_event.v1"
accession: "0001564590-21-042675"
form_type: "8-K"
ticker: "FLGT"
cik: "0001674930"
company_name: "Fulgent Genetics, Inc."
filed_at: "2021-08-09T23:59:59+00:00"
generated_at: "2026-06-29T18:55:52.632319+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Fulgent Genetics Q2 revenue $153.6M (+790% YoY); acquires CSI Labs, invests in Helio Health and FF Gene Biotech

## Summary
- Q2 revenue $153.6M (+790% YoY); ~1.6M billable tests (9x YoY); gross margin improved ~21pp YoY.
- GAAP net income $79.8M ($2.59 EPS); non-GAAP net income $78.7M ($2.55 EPS); adjusted EBITDA $105.0M.
- Core (NGS) revenue grew 296% YoY to $25.7M.
- Acquisition of CSI Laboratories (cancer diagnostics) and commercial agreement with Helio Health via strategic investment.
- Incremental controlling investment in Chinese JV FF Gene Biotech.

## SEC filing metadata
- accession: 0001564590-21-042675
- form_type: 8-K
- ticker: FLGT
- cik: 0001674930
- company_name: Fulgent Genetics, Inc.
- filed_at: 2021-08-09T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1674930/000156459021042675/0001564590-21-042675-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1674930/000156459021042675/flgt-8k_20210809.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001564590-21-042675
- JSON: https://secwatch.observer/filing/0001564590-21-042675.json
- Plain text: https://secwatch.observer/filing/0001564590-21-042675.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.